医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Study to Evaluate Safety and Efficacy of Fuzheng Huayu as an Anti-Fibrotic Treatment in U.S. Hepatitis C Patients Nears Completion

2012年11月13日 PM11:55
このエントリーをはてなブックマークに追加


 

BOSTON

During its Nov. 11 advisory board meeting at the 2012 Liver Meeting® of the American Association for the Study of Liver Diseases, Shanghai Sundise Traditional Chinese Medicine Co., Ltd. (Sundise) announced that the Phase II U.S. Clinical Trial to validate the botanical drug Fuzheng Huayu (FZHY) as a treatment for liver fibrosis in hepatitis C is close to completion. The company also invited the investigators and the data management team to review the study’s progress.

“At this point, 73 percent of the patients have completed the post-treatment liver biopsy and 60 percent have finished the 60-week study,” said Huashi Bian, Sundise CEO. “The last patient is expected to complete the study in February 2013.”

Tarek Hassanein, MD, director of SCTI Research Foundation and lead principal investigator, confirmed that the study was progressing well, as planned, and the results are expected to be announced in the second half of 2013. He also added that, per the Data Monitoring Committee, no changes need to be made to the protocol.

Manufactured by Sundise, FZHY is an approved anti-fibrotic drug for treating hepatitis B infection in China, Singapore and Hong Kong. Clinical trials conducted in China show FZHY improves hepatic inflammation, regulates fat metabolism, reduces liver fibrosis scores and inhibits fibrosis progression into cirrhosis.

The U.S. Phase II trial was initiated in 2009 for the treatment of liver fibrosis in hepatitis C patients. It is a multicenter, double blinded and placebo-controlled trial evaluating treatment with FZHY for one year and pre- and post-treatment liver biopsy assessments. Detailed trial information is available at www.clinicaltrials.gov (Identifier: NCT00854087).

A worldwide team of three pathologists has been formed to carry out the study’s next step: evaluating patients’ liver biopsies in a standardized and reliable manner.

“State-of-art scanning technology on liver biopsy slides has made the international collaboration an easy process,” Bian added. “Once patients’ liver biopsy slides are scanned and stored on the centrally hosted web servers, three pathologists around the world will review digitalized images through secure Internet access.”

Shanghai Sundise Traditional Chinese Medicine Co., Ltd. is a technology corporation specialized in the modernization of Traditional Chinese Medicine, based in Shanghai, China. Sundise works closely with universities and research institutes across China and the United States to conduct studies on therapeutic compounds based on the Chinese traditional medicine. Learn more about Sundise and its products at http://www.sundise.com.

CONTACT

Shanghai Sundise Co., Ltd.
Dan Wen, MD, 602-690-4668
dan.wen@sundise.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明
  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結